Instil Bio, Inc. Operating Expenses
Instil Bio, Inc. (TIL) reported Operating Expenses of $5.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Instil Bio, Inc. operating expenses for the quarter ending 2026-06-30 was $5.58M, a 76.19% decline year-over-year.
- Instil Bio, Inc. operating expenses for the quarter ending 2026-03-31 was $7.01M, a 77.06% decline year-over-year.
- Instil Bio, Inc. operating expenses for the quarter ending 2025-12-31 was $9.56M, a 19.14% decline year-over-year.
- Instil Bio, Inc. operating expenses for the quarter ending 2025-09-30 was $15.02M, a 36.43% decline year-over-year.
- Instil Bio, Inc. operating expenses for fiscal 2025 was $78.58M, a 6.85% increase from fiscal 2024.
- Instil Bio, Inc. operating expenses for fiscal 2024 was $73.54M, a 53.80% decline from fiscal 2023.
- Instil Bio, Inc. operating expenses for fiscal 2023 was $159.17M, a 29.71% decline from fiscal 2022.
- Instil Bio, Inc. operating expenses for fiscal 2022 was $226.46M, a 45.58% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.58M 10-Q · filed 2026-08-13 | $12.59M 10-Q · filed 2026-08-13 | $22.15M derived: sum of 3 quarters · filed 2026-08-13 | $37.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $7.01M 10-Q · filed 2026-05-15 | $16.57M derived: sum of 2 quarters · filed 2026-05-15 | $31.59M derived: sum of 3 quarters · filed 2026-05-15 | $55.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $9.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $24.58M derived: sum of 2 quarters · filed 2026-03-27 | $48.02M derived: sum of 3 quarters · filed 2026-08-13 | $78.58M 10-K · filed 2026-03-27 |
| 2025-09-30 | $15.02M 10-Q · filed 2025-11-13 | $38.46M derived: sum of 2 quarters · filed 2026-08-13 | $69.02M 10-Q · filed 2025-11-13 | $80.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $23.44M 10-Q · filed 2026-08-13 | $54.00M 10-Q · filed 2026-08-13 | $65.82M derived: sum of 3 quarters · filed 2026-08-13 | $89.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $30.56M 10-Q · filed 2026-05-15 | $42.38M derived: sum of 2 quarters · filed 2026-05-15 | $66.01M derived: sum of 3 quarters · filed 2026-05-15 | $80.15M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $11.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $35.45M derived: sum of 2 quarters · filed 2026-03-27 | $49.59M derived: sum of 3 quarters · filed 2026-03-27 | $73.54M 10-K · filed 2026-03-27 |
| 2024-09-30 | $23.63M 10-Q · filed 2025-11-13 | $37.77M derived: sum of 2 quarters · filed 2025-11-13 | $61.72M 10-Q · filed 2025-11-13 | $74.74M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $14.13M 10-Q · filed 2025-08-13 | $38.09M 10-Q · filed 2025-08-13 | $51.11M derived: sum of 3 quarters · filed 2025-08-13 | $117.83M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $23.95M 10-Q · filed 2025-05-13 | $36.98M derived: sum of 2 quarters · filed 2025-05-13 | $103.69M derived: sum of 3 quarters · filed 2025-05-13 | $124.68M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $13.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $79.74M derived: sum of 2 quarters · filed 2025-03-04 | $100.72M derived: sum of 3 quarters · filed 2025-03-04 | $159.17M 10-K · filed 2025-03-04 |
| 2023-09-30 | $66.72M 10-Q · filed 2024-11-13 | $87.70M derived: sum of 2 quarters · filed 2024-11-13 | $146.15M 10-Q · filed 2024-11-13 | $202.95M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $20.99M 10-Q · filed 2024-08-13 | $79.43M 10-Q · filed 2024-08-13 | $136.23M derived: sum of 3 quarters · filed 2024-08-13 | $192.88M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $58.45M 10-Q · filed 2024-05-10 | $115.25M derived: sum of 2 quarters · filed 2024-05-10 | $171.89M derived: sum of 3 quarters · filed 2024-05-10 | $230.62M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $56.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $113.45M derived: sum of 2 quarters · filed 2024-03-21 | $172.17M derived: sum of 3 quarters · filed 2024-03-21 | $226.46M 10-K · filed 2024-03-21 |
| 2022-09-30 | $56.65M 10-Q · filed 2023-11-13 | $115.37M derived: sum of 2 quarters · filed 2023-11-13 | $169.66M 10-Q · filed 2023-11-13 | $223.41M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $58.72M 10-Q · filed 2023-08-14 | $113.01M 10-Q · filed 2023-08-14 | $166.76M derived: sum of 3 quarters · filed 2023-08-14 | $209.79M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $54.29M 10-Q · filed 2023-05-11 | $108.04M derived: sum of 2 quarters · filed 2023-05-11 | $151.06M derived: sum of 3 quarters · filed 2023-05-11 | $186.44M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $53.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $96.78M derived: sum of 2 quarters · filed 2023-03-31 | $132.16M derived: sum of 3 quarters · filed 2023-03-31 | $155.56M 10-K · filed 2023-03-31 |
| 2021-09-30 | $43.02M 10-Q · filed 2022-11-14 | $78.41M derived: sum of 2 quarters · filed 2022-11-14 | $101.81M 10-Q · filed 2022-11-14 | $119.28M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $35.38M 10-Q · filed 2022-08-12 | $58.78M 10-Q · filed 2022-08-12 | $76.26M derived: sum of 3 quarters · filed 2022-08-12 | $84.02M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $23.40M 10-Q · filed 2022-05-16 | $40.88M derived: sum of 2 quarters · filed 2022-05-16 | $48.64M derived: sum of 3 quarters · filed 2022-05-16 | $53.28M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $25.24M derived: sum of 2 quarters · filed 2022-03-07 | $29.88M derived: sum of 3 quarters · filed 2022-03-07 | $33.78M 10-K · filed 2022-03-07 |
| 2020-09-30 | $7.76M 10-Q · filed 2021-11-15 | $12.40M derived: sum of 2 quarters · filed 2021-11-15 | $16.30M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $4.63M 10-Q · filed 2021-08-12 | $8.54M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.91M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |